Evidence map›Paper›PMID 39549228›Full record

SynthesisClinical pharmacokinetics2024

Time-Efficacy Relationship of Semaglutide in the Treatment of Type 2 Diabetes Mellitus: A Model-Based Meta-Analysis.

Ke Zhang, Aiping Zhao, Zhen Wang, Kaihe Ye, Zhaosi Xu, Xiao Gong, Guanghu Zhu

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Clinical pharmacokinetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ke ZhangSchool of Mathematics and Computing Science, Guangxi Colleges and Universities Key Laboratory of Data Analysis and Computation, Guilin University of Electronic Technology, Jinji Road No 1, Qixing District, Guilin, 541004, China.
Aiping ZhaoSchool of Mathematics and Computing Science, Guangxi Colleges and Universities Key Laboratory of Data Analysis and Computation, Guilin University of Electronic Technology, Jinji Road No 1, Qixing District, Guilin, 541004, China.
Zhen WangSchool of Mathematics and Computing Science, Guangxi Colleges and Universities Key Laboratory of Data Analysis and Computation, Guilin University of Electronic Technology, Jinji Road No 1, Qixing District, Guilin, 541004, China.
Kaihe YeDepartment of Biostatistics, Guangzhou Jeeyor Medical Research Co., Ltd,, Room 536, Building 4, Ground 7, Guangzhou International Airport Center, Yingbin Avenue, Huadu District, Guangzhou, 510000, China.
Zhaosi XuDepartment of Biostatistics, Guangzhou Jeeyor Medical Research Co., Ltd,, Room 536, Building 4, Ground 7, Guangzhou International Airport Center, Yingbin Avenue, Huadu District, Guangzhou, 510000, China.
Xiao GongDepartment of Biostatistics, Guangzhou Jeeyor Medical Research Co., Ltd,, Room 536, Building 4, Ground 7, Guangzhou International Airport Center, Yingbin Avenue, Huadu District, Guangzhou, 510000, China. x.gong@foxmail.com.
Guanghu ZhuSchool of Mathematics and Computing Science, Guangxi Colleges and Universities Key Laboratory of Data Analysis and Computation, Guilin University of Electronic Technology, Jinji Road No 1, Qixing District, Guilin, 541004, China. ghzhu@guet.edu.cn.ORCID 0000-0002-1416-1476

Funding

Director Fund Project of the Ministry of Education Key Laboratory of Cognitive Radio and Information Processing CRKL210106Natural Science Foundation of Guangxi Province 2024GXNSFAA010475Science and Technology Project of Guangxi Guike AD23023002
6 · The paper itself

Abstract

objectiveOur objective was to quantify the efficacy of subcutaneous once-weekly semaglutide in treating type 2 diabetes mellitus (T2DM) over time.

methodsBased on a literature search of the PubMed, Embase, Cochrane, and Web of Science databases, a modified maximum effect (E

resultsE

conclusionThe efficacy of semaglutide in glucose control was investigated using the model-based meta-analysis method, which yields new insights into the treatment of T2DM with semaglutide.

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsBlood GlucoseDose-Response Relationship, DrugFemaleGlycated HemoglobinHumansMaleModels, BiologicalSemaglutideTreatment OutcomeBlood GlucoseGlucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsSemaglutide

Identifiers

PMID39549228

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.